CA Patent

CA2746527A1 — Rna interference in skin indications

Assigned to Phio Pharmaceuticals Corp · Expires 2010-03-25 · 16y expired

What this patent protects

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.

USPTO Abstract

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: CA2746527A1
Jurisdiction: CA
Classification: —
Expires: 2010-03-25
Drug substance claim: No
Drug product claim: No
Assignee: Phio Pharmaceuticals Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.